FeesSafety
Pluang+

Vertex and Regeneron rebound with strong drug pipelines and new product approvals boosting growth.

Market News
20 Nov 2026, 00:43 WIB
Prosper Junior Bakiny
View Source
Bullish
Vertex and Regeneron rebound with strong drug pipelines and new product approvals boosting growth.

Vertex Pharmaceuticals is poised for growth with potential FDA approval of povetacicept for kidney disease and a strong cystic fibrosis drug franchise, alongside a $10 billion acquisition expanding its pipeline. Regeneron is thriving with Dupixent's robust sales and a new Eylea formulation mitigating declines, supported by a diverse pipeline in oncology and other areas. Both companies have delivered above-average returns in 2026 and show promising prospects for continued financial success and new product launches in the coming years.

Vertex Pharmaceuticals trades at USD 524.65 on Pluang as of Nov 20, 2026 01:11 WIB, down 2.20% in one day. Regeneron shares are priced at USD 937.50, down 0.85% on the same date. Both stocks show strong market caps, with Vertex at $136.01B and Regeneron at $97.81B, while most Pluang users are currently selling these shares.

More News (VRTX)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App